Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas Nissen

Showing results (11-20 of 63) with videos related to

Pageof 7
Sort By:
The American Surgeon|February 3, 2018
Prognostic Factors Associated with Outcomes in Small Bowel Neuroendocrine TumorsNicholas Manguso, Jeffrey Johnson, Attiya Harit, et al.
Cancer Research|July 22, 2010
Fructose induces transketolase flux to promote pancreatic cancer growthHaibo Liu, Danshan Huang, David L McArthur, et al.
Plos One|March 26, 2016
Influence of Body Mass Index and Albumin on Perioperative Morbidity and Clinical Outcomes in Resected Pancreatic AdenocarcinomaAndrew Hendifar, Arsen Osipov, Jasleen Khanuja, et al.
World Journal of Hepatology|October 13, 2016
Management of refractory ascites in cirrhosis: Are we out of date?Alagappan Annamalai, Lauren Wisdom, Megan Herada, et al.
Journal of Gastrointestinal Oncology|March 11, 2017
Identifying prognostic intratumor heterogeneity using pre- and post-radiotherapy 18F-FDG PET images for pancreatic cancer patientsYong Yue, Arsen Osipov, Benedick Fraass, et al.
JCO Precision Oncology|January 20, 2022
Exploiting Temozolomide-Induced Hypermutation With Pembrolizumab in a Refractory High-Grade Neuroendocrine Neoplasm: A Proof-of-Concept CaseSamuel J Klempner, Andrew Hendifar, Kevin M Waters, et al.
JCO Precision Oncology|February 17, 2022
Anaplastic Lymphoma Kinase Rearrangement and Response to Crizotinib in Pancreatic Ductal AdenocarcinomaRichard Tuli, Simon Lo, Jaimie Koo, et al.
Clinical Case Reports|March 2, 2023
Linear IgA bullous dermatosis and elevated bullous interleukin-6 levels: Responsive to treatment with Anti-IL-6 receptor monoclonalsStanley C Jordan, Bonnie Balzer, Cynthia Nast, et al.
Journal of Surgical Oncology|August 10, 2019
Prognostic factors influencing survival in small bowel neuroendocrine tumor with liver metastasesNicholas Manguso, Nicholas Nissen, Andrew Hendifar, et al.
Archives of Surgery (Chicago, Ill. : 1960)|September 21, 2005
Morbidity in live liver donors: standards-based adverse event reporting further refinedChristopher R Shackleton, John M Vierling, Nicholas Nissen, et al.
Pageof 7

Showing results (11-20 of 63) with videos related to

Sort By:
Pageof 7
The American Surgeon|February 3, 2018
Prognostic Factors Associated with Outcomes in Small Bowel Neuroendocrine TumorsNicholas Manguso, Jeffrey Johnson, Attiya Harit, et al.
Cancer Research|July 22, 2010
Fructose induces transketolase flux to promote pancreatic cancer growthHaibo Liu, Danshan Huang, David L McArthur, et al.
Plos One|March 26, 2016
Influence of Body Mass Index and Albumin on Perioperative Morbidity and Clinical Outcomes in Resected Pancreatic AdenocarcinomaAndrew Hendifar, Arsen Osipov, Jasleen Khanuja, et al.
World Journal of Hepatology|October 13, 2016
Management of refractory ascites in cirrhosis: Are we out of date?Alagappan Annamalai, Lauren Wisdom, Megan Herada, et al.
Journal of Gastrointestinal Oncology|March 11, 2017
Identifying prognostic intratumor heterogeneity using pre- and post-radiotherapy 18F-FDG PET images for pancreatic cancer patientsYong Yue, Arsen Osipov, Benedick Fraass, et al.
JCO Precision Oncology|January 20, 2022
Exploiting Temozolomide-Induced Hypermutation With Pembrolizumab in a Refractory High-Grade Neuroendocrine Neoplasm: A Proof-of-Concept CaseSamuel J Klempner, Andrew Hendifar, Kevin M Waters, et al.
JCO Precision Oncology|February 17, 2022
Anaplastic Lymphoma Kinase Rearrangement and Response to Crizotinib in Pancreatic Ductal AdenocarcinomaRichard Tuli, Simon Lo, Jaimie Koo, et al.
Clinical Case Reports|March 2, 2023
Linear IgA bullous dermatosis and elevated bullous interleukin-6 levels: Responsive to treatment with Anti-IL-6 receptor monoclonalsStanley C Jordan, Bonnie Balzer, Cynthia Nast, et al.
Journal of Surgical Oncology|August 10, 2019
Prognostic factors influencing survival in small bowel neuroendocrine tumor with liver metastasesNicholas Manguso, Nicholas Nissen, Andrew Hendifar, et al.
Archives of Surgery (Chicago, Ill. : 1960)|September 21, 2005
Morbidity in live liver donors: standards-based adverse event reporting further refinedChristopher R Shackleton, John M Vierling, Nicholas Nissen, et al.
Pageof 7